Lamivudine, tenofovir disoproxil fumerate (Lamivudine And Tenofovir Cipla)
Lamivudine, tenofovir disoproxil fumerate
Cipla Medpro (Pty) Ltd
Registration
- Applicant
- Cipla Medpro (Pty) Ltd
- Registrations
- 1
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Lamivudine and tenofovir 300/300 cipla Each Tablet contains: Lamivudine 300 mg; Tenofovir Disoproxil Fumerate 300 g | 300/300 | 51057251/20.2.8/572 | Registered | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.